Prevalence of Cough among patients on Perindopril in Duhok City

Perindopril is an an angiotensin-converting enzyme (ACE) inhibitor, newly introduced into Iraqi market and widely prescribed for hypertension and cardiovascular disorders. Cough as a usual side effect associated with ACE inhibitors vary based on ethnic group. The present study thought to Determine the prevalence perindopril-associated cough as new introducers in Iraqi market.

This cross sectional study was conducted in adult (aged>18 ) hypertensive patients visiting private clinics in Duhok city, who had been treated by perindopril for at least two weeks. A questionnaire was handed to individuals to collect demographic data, duration and indication of perindopril use, presence of cough, time of onset of cough, and comorbidities.

The results revealed that 61% (n=51) of participants accepted the perindopril without cough, while 39% (n=33) demonstrated non-tolerable cough. The prevalence of tolerability in male (76.7%) and female (83.3) patients were higher compared to non-tolerable participants. Patients aged ≤50 years demonstrated higher cough tolerability (72%). However, >50 years old participants demonstrated lower tolerability rates (55.9%), with 44.1% demonstrated non-tolerable cough.

Perindopril has induced a higher non-tolerable cough in younger age group regardless of gender differences or residency status.